NCT06163040 2025-07-31A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanBristol-Myers SquibbCompleted7 enrolled
NCT02555839 2025-03-28Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical PracticeCelgeneCompleted127 enrolled
NCT02556905 2017-12-04A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in KoreaCelgeneCompleted624 enrolled